Precision BioSciences Wins FDA Fast Track for First Gene-Editing Therapy Targeting Duchenne Muscular Dystrophy, Prepares to Dose Children in Phase 1/2 Trial
Precision BioSciences receives FDA Fast Track for PBGENE-DMD, a gene-editing therapy that excises faulty exons to restore near full-length dystrophin in up to 60 percent of Duchenne patients.
4 min read3 sources